Unlock instant, AI-driven research and patent intelligence for your innovation.

A method for predicting coagulation dysfunction due to amniotic fluid embolism

A technology for coagulation dysfunction and amniotic fluid embolism, which is applied in the field of coagulation detection, can solve problems such as changes and failure to achieve fibrinolysis indicators, and achieve the effect of preventing amniotic fluid embolism

Active Publication Date: 2020-02-18
杨江存
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Miriam J.P.Harnett used thromboelastography to observe the effect of amniotic fluid on the blood coagulation function of pregnant women in vitro. The study believed that amniotic fluid further stimulated the occurrence of hypercoagulation, but the experiment did not achieve changes in fibrinolysis indicators

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for predicting coagulation dysfunction due to amniotic fluid embolism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] This embodiment provides a method for predicting coagulation dysfunction of amniotic fluid embolism based on thromboelastography, comprising the following steps:

[0024] (1) 5 μl of kaolin solution with a concentration of 0.5 mg / ml was fully mixed with 300 μl of blood sample to activate the blood sample, and the activation time was 3 minutes to obtain the activated blood sample;

[0025] (2) Add the blood sample after the activation into a sample cup containing 15 μl of 0.5 mol / L calcium chloride solution, then slowly add 5 μl of amniotic fluid and 5 μl of urokinase to the sample cup (the enzyme activity of urokinase 20U / ml), to obtain the blood sample to be tested;

[0026] (3) Place the blood sample to be tested in a thromboelastography apparatus for testing to obtain the LY30 value of the fibrinolysis index. When the LY30 value is ≧7.5, the incidence of amniotic fluid embolism and coagulation dysfunction in this pregnant woman is relatively high, and intervention sh...

Embodiment 2

[0028] This embodiment provides a method for predicting coagulation dysfunction of amniotic fluid embolism based on thromboelastography, comprising the following steps:

[0029] (1) First use 15 μl of kaolin solution with a concentration of 0.2 mg / ml to fully mix with 400 μl of blood sample to activate the blood sample, and the activation time is 6 minutes to obtain the activated blood sample;

[0030] (2) Add the activated blood sample into a sample cup containing 25 μl of 0.1mol / L calcium chloride solution, then slowly add 30 μl of amniotic fluid and 30 μl of urokinase to the sample cup (the enzyme activity of urokinase 200U / ml), to obtain the blood sample to be tested;

[0031] (3) Place the blood sample to be tested in a thromboelastography apparatus for testing to obtain the LY30 value of the fibrinolysis index. When the LY30 value is ≧7.5, the incidence of amniotic fluid embolism and coagulation dysfunction in this pregnant woman is relatively high, and intervention shou...

Embodiment 3

[0033] This embodiment provides a method for predicting coagulation dysfunction of amniotic fluid embolism based on thromboelastography, comprising the following steps:

[0034] (1) First use 10 μl of kaolin solution with a concentration of 0.4 mg / ml to fully mix with 340 μl of blood sample to activate the blood sample, and the activation time is 4 minutes to obtain the activated blood sample;

[0035] (2) Add the activated blood sample into a sample cup containing 20 μl of 0.3mol / L calcium chloride solution, then slowly add 10 μl of amniotic fluid and 10 μl of urokinase to the sample cup (the enzyme activity of urokinase 58U / ml), to obtain the blood sample to be tested;

[0036] (3) Place the blood sample to be tested in a thromboelastography apparatus for testing. When the LY30 value is ≧7.5, the incidence of amniotic fluid embolism and coagulation dysfunction in this pregnant woman is relatively high, and intervention measures should be taken in advance.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a predicating method for amniotic fluid embolism coagulation disorders. The predicating method is characterized in that amniotic fluid and urokinase with proper concentration are adopted to perform in-vitro induction on whole blood of a pregnant woman by adopting a thrombelastogram which can reflect a blood coagulation process and fibrinolysis full view, so that blood is motivated to have a high-coagulation and fibrinolysis process; indexes of the thrombelastogram change to evaluate sensibility and tolerance, on amniotic fluid and urokinase, of the pregnant woman, so that possibility that blood coagulation disorders is caused by amniotic fluid is predicated; when an LY30 value is greater than or equal to 7.5, the occurrence rate of the amniotic fluid embolism coagulation disorders of the pregnant women is relatively high, and therefore, screening must be performed in advance and measures must be taken to prevent occurrence of amniotic fluid embolism.

Description

technical field [0001] The invention belongs to the technical field of coagulation detection, and in particular relates to a method for predicting coagulation dysfunction due to amniotic fluid embolism. Background technique [0002] Amniotic fluid embolism is a hypersensitivity syndrome of pregnancy, and patients usually present with anaphylactic shock and acute pulmonary embolism. Some researchers also believe that amniotic fluid embolism is a consumptive coagulopathy. Patients show a large amount of coagulation substance consumption and hyperfibrinolysis, and maternal hemorrhage all over the body, resulting in maternal hemorrhage and death. At present, there is no experimental method for preventive detection. If it is possible to predict and screen high-risk groups of amniotic fluid embolism and coagulation dysfunction before delivery, it is of great significance to establish a sensitive and reliable test method. Miriam J.P.Harnett used thrombelastography to observe the e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/86
CPCG01N33/86G01N2800/224G01N2800/368
Inventor 杨江存
Owner 杨江存